晚期前列腺癌的临床管理:放射性药物治疗在治疗算法中的定位
本文综述转移性前列腺癌当前治疗格局,重点讨论放射性药物治疗尤其是177Lu-PSMA-617在转移性去势抵抗性前列腺癌中的定位。文章梳理177Lu-PSMA-617的临床挑战,探讨将其用于联合方案或更早治疗阶段的探索性研究,并介绍其他在研放射性药物。
要点
- 转移性前列腺癌 backbone 为雄激素受体靶向治疗联合或不联合紫杉烷化疗。
- 177Lu-PSMA-617是转移性去势抵抗性前列腺癌的非雄激素受体靶向治疗选择,可影响患者生存。
- 177Lu-PSMA-617用于联合方案或更早治疗阶段的研究正在进行,其他放射性药物尚待进一步研究。
核心结论
- 放射性药物治疗已成为转移性去势抵抗性前列腺癌的非雄激素受体靶向治疗选择,可影响患者生存,并代表一种可能更具个体化的治疗方式。
- 将放射性药物用于联合方案或更早治疗阶段以进一步改善患者结局的探索正在进行中。
- 其他放射性药物在转移性前列腺癌中的研究仍在进行,需进一步研究后方可能纳入治疗算法。
研究设计与样本
- 综述,围绕转移性前列腺癌当前治疗格局展开,重点关注放射性药物治疗,特别是177Lu-PSMA-617。
主要发现
- 多数新诊断转移性前列腺癌患者以雄激素受体靶向治疗联合或不联合紫杉烷化疗为 backbone 进行最优治疗。
- 尽管疾病结局有所改善,前列腺癌仍具高度异质性,治疗耐药机制多变,仍是男性癌症相关死亡的主要原因之一。
- 177Lu-PSMA-617治疗至今存在多种临床挑战。
局限性
- 其他放射性药物在转移性前列腺癌中的应用尚待进一步研究后方可能纳入治疗算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most men with newly appreciated metastatic prostate cancer are optimally treated with a backbone consisting of androgen receptor-directed therapy with or without taxane chemotherapy. Despite improvements in disease outcomes, prostate cancer remains an extremely heterogeneous disease with variable mechanisms of therapeutic resistance. As a result, it remains a leading cause of cancer-related death in men. Radiopharmaceutical therapy has emerged as an alternative, non-androgen receptor-directed treatment modality for metastatic castration-resistant prostate cancer that impacts patient survival and represents a potentially more personalized approach. In this review, we aim to outline the current treatment landscape for metastatic prostate cancer with a focus on radiopharmaceutical therapy, specifically 177Lu-PSMA-617. In addition, we illustrate various clinical challenges with 177Lu-PSMA-617 treatment to date and explore investigative efforts to leverage radiopharmaceutical therapies as part of combination regimens or earlier in the treatment algorithm to further improve patient outcomes. Finally, we introduce ongoing studies of alternative radiopharmaceutical therapies in metastatic prostate cancer that may be incorporated into the treatment algorithm pending further study.
引用
- Viscuse P, Devitt M, Dreicer R, et al. Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm? J Nucl Med. 2024. PMID: 38604761. doi:10.2967/jnumed.123.267006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。